SLC5A2 and lactic acidosis: For example, with metformin there is an increased risk of lactic acidosis with an eGFR of less than 30 ml/min/1.73m2, as opposed to SGLT2 inhibitors where the issue is not so much one of safety but that these agents are not effective in lowering glucose levels at a reduced eGFR.